{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:26:23Z","timestamp":1783571183818,"version":"3.55.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000774","name":"Newcastle University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UKRI Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P002854\/1"],"award-info":[{"award-number":["MR\/P002854\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bcp.2024.116499","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T13:08:07Z","timestamp":1724332087000},"page":"116499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants"],"prefix":"10.1016","volume":"229","author":[{"given":"Brian E.","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti S.","family":"Chachra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alshawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Oakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Fairclough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tiniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-6503","authenticated-orcid":false,"given":"Loranne","family":"Agius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116499_b0005","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrd4231","article-title":"Targeting the pancreatic \u03b2-cell to treat diabetes","volume":"13","author":"Vetere","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.bcp.2024.116499_b0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2850","article-title":"Assessing the potential of glucokinase activators in diabetes therapy","volume":"8","author":"Matschinsky","year":"2009","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.bcp.2024.116499_b0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/13543776.2014.918957","article-title":"A patent review of glucokinase activators and disruptors of the glucokinase\u2013glucokinase regulatory protein interaction: 2011\u20132014","volume":"24","author":"Filipski","year":"2014","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2024.116499_b0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41591-022-01802-6","article-title":"Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2024.116499_b0025","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41591-022-01803-5","article-title":"Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Yang","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2024.116499_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101604","article-title":"A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial - implications for therapeutic immune modulation","volume":"51","author":"Chorlton","year":"2022","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.bcp.2024.116499_b0035","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/dom.14909","article-title":"A multicentre, randomized, double-blind, parallel, active- and placebo-controlled Phase 3 clinical study of the glucokinase activator PB-201 in treatment-naive patients with type 2 diabetes mellitus: A study protocol","volume":"25","author":"Du","year":"2023","journal-title":"Diabetes. Obes. Metab."},{"issue":"475","key":"10.1016\/j.bcp.2024.116499_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3441","article-title":"Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator","volume":"11","author":"Vella","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116499_b0045","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-022-01783-6","article-title":"A new class of drug in the diabetes toolbox","volume":"28","author":"Klein","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2024.116499_b0050","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc11-1200","article-title":"Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes","volume":"34","author":"Meininger","year":"2011","journal-title":"Diabetes. Care."},{"key":"10.1016\/j.bcp.2024.116499_b0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/dom.12088","article-title":"Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin","volume":"15","author":"Wilding","year":"2013","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0060","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/dom.12100","article-title":"Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Kiyosue","year":"2013","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.tips.2012.11.007","article-title":"GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?","volume":"34","author":"Matschinsky","year":"2013","journal-title":"Trends. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2024.116499_b0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/jdi.12294","article-title":"Present status of clinical deployment of glucokinase activators","volume":"6","author":"Nakamura","year":"2015","journal-title":"J. Diabetes. Investig."},{"key":"10.1016\/j.bcp.2024.116499_b0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2011.05.009","article-title":"Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice","volume":"663","author":"Winzell","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116499_b0080","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/dom.14111","article-title":"Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge","volume":"22","author":"Ford","year":"2020","journal-title":"Diabetes. Obes. Metab."},{"issue":"668","key":"10.1016\/j.bcp.2024.116499_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1316","article-title":"Chronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats","volume":"14","author":"Kroon","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116499_b0090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.2040-1124.2011.00104.x","article-title":"Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function","volume":"2","author":"Nakamura","year":"2011","journal-title":"J. Diabetes. Investig."},{"key":"10.1016\/j.bcp.2024.116499_b0095","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/bph.12504","article-title":"Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes","volume":"171","author":"Baker","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116499_b0100","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1463-1326.2007.00819.x","article-title":"Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice","volume":"10","author":"Gorman","year":"2008","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0105","doi-asserted-by":"crossref","first-page":"e0265761","DOI":"10.1371\/journal.pone.0265761","article-title":"Disruptions in hepatic glucose metabolism are involved in the diminished efficacy after chronic treatment with glucokinase activator","volume":"17","author":"Tsumura","year":"2022","journal-title":"PLoS. One."},{"key":"10.1016\/j.bcp.2024.116499_b0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1126\/science.1084073","article-title":"Allosteric activators of glucokinase: potential role in diabetes therapy","volume":"301","author":"Grimsby","year":"2003","journal-title":"Science."},{"key":"10.1016\/j.bcp.2024.116499_b0115","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bph.12172","article-title":"S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice","volume":"169","author":"De Ceuninck","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116499_b0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/dom.14586","article-title":"Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db\/db mice","volume":"24","author":"Kawata","year":"2022","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0125","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fendo.2020.00378","article-title":"Reducing Glucokinase Activity to Enhance Insulin Secretion: A Counterintuitive Theory to Preserve Cellular Function and Glucose Homeostasis","volume":"11","author":"Whitticar","year":"2020","journal-title":"Front. Endocrinol. (lausanne)."},{"key":"10.1016\/j.bcp.2024.116499_b0130","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1172\/JCI117256","article-title":"In situ glucose uptake and glucokinase activity of pancreatic islets in diabetic and obese rodents","volume":"93","author":"Liang","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2024.116499_b0135","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/db20-0881","article-title":"Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing \u03b2-Cell Mass in db\/db Mice","volume":"70","author":"Omori","year":"2021","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2024.116499_b0140","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1210\/en.2018-00589","article-title":"Reducing Glucokinase Activity Restores Endogenous Pulsatility and Enhances Insulin Secretion in Islets From db\/db Mice","volume":"159","author":"Jahan","year":"2018","journal-title":"Endocrinology."},{"key":"10.1016\/j.bcp.2024.116499_b0145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev-nutr-071715-051145","article-title":"Hormonal and Metabolite Regulation of Hepatic Glucokinase","volume":"36","author":"Agius","year":"2016","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.bcp.2024.116499_b0150","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1096\/fasebj.8.6.8168691","article-title":"Short-term control of glucokinase activity: role of a regulatory protein","volume":"8","author":"Van Schaftingen","year":"1994","journal-title":"FASEB. J."},{"key":"10.1016\/j.bcp.2024.116499_b0155","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2024.116499_b0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1042\/BJ20131363","article-title":"Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence","volume":"459","author":"Zelent","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2024.116499_b0165","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.2337\/db08-0516","article-title":"Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations","volume":"57","author":"Orho-Melander","year":"2008","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2024.116499_b0170","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molmed.2015.08.004","article-title":"Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?","volume":"21","author":"Brouwers","year":"2015","journal-title":"Trends. Mol. Med."},{"key":"10.1016\/j.bcp.2024.116499_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101722","article-title":"The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326","volume":"72","author":"Ford","year":"2023","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0180","doi-asserted-by":"crossref","first-page":"765","DOI":"10.5414\/CP201747","article-title":"Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp","volume":"50","author":"Ericsson","year":"2012","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116499_b0185","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1463-1326.2012.01661.x","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus","volume":"14","author":"Morrow","year":"2012","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0190","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology."},{"key":"10.1016\/j.bcp.2024.116499_b0195","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3389\/fphar.2020.01279","article-title":"Hypoxia-Induced Adipose Lipolysis Requires Fibroblast Growth Factor 21","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116499_b0200","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cells8030238","article-title":"CIDE Proteins in Human Health and disease","volume":"8","author":"Slayton","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.bcp.2024.116499_b0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0028-1095102","article-title":"Hepatic enzyme activities of glycolysis and gluconeogenesis in diabetes of man and laboratory animals","volume":"2","author":"Willms","year":"1970","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bcp.2024.116499_b0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/1753-0407.13380","article-title":"\u03b2-Cell glucokinase expression was increased in type 2 diabetes subjects with better glycemic control","volume":"15","author":"Liu","year":"2023","journal-title":"J. Diabetes."},{"key":"10.1016\/j.bcp.2024.116499_b0215","doi-asserted-by":"crossref","unstructured":"J.M. Dennis, B.M. Shields, A.V. Hill, B.A. Knight, T.J. McDonald, L.R. Rodgers, et al. MASTERMIND Consortium. precision medicine in Type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care. 2018;41:705-712. doi: 10.2337\/dc17-1827.","DOI":"10.2337\/dc17-1827"},{"key":"10.1016\/j.bcp.2024.116499_b0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13073-017-0453-x","article-title":"Identification and characterization of a FOXA2-regulated transcriptional enhancer at a type 2 diabetes intronic locus that controls GCKR expression in liver cells","volume":"9","author":"L\u00f3pez Rodr\u00edguez","year":"2017","journal-title":"Genome. Med."},{"key":"10.1016\/j.bcp.2024.116499_b0225","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2013.06.015","article-title":"Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db\/db mice","volume":"714","author":"Dhanesha","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116499_b0230","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1152\/ajplegacy.1975.229.6.1702","article-title":"Hepatic metabolism of genetically diabetic (db\/db) mice. I. Carbohydrate Metabolism","volume":"229","author":"Chan","year":"1975","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.bcp.2024.116499_b0235","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.2337\/db11-0061","article-title":"Elevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasis","volume":"60","author":"Arden","year":"2011","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2024.116499_b0240","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/dom.12910","article-title":"Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes","volume":"19","author":"Al-Oanzi","year":"2017","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0245","doi-asserted-by":"crossref","first-page":"5812607","DOI":"10.1155\/2017\/5812607","article-title":"Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus","volume":"2017","author":"Wang","year":"2017","journal-title":"J. Diabetes. Res."},{"key":"10.1016\/j.bcp.2024.116499_b0250","doi-asserted-by":"crossref","first-page":"14511","DOI":"10.1073\/pnas.96.25.14511","article-title":"Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation","volume":"96","author":"Farrelly","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2024.116499_b0255","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1074\/jbc.275.11.7826","article-title":"Characterization of glucokinase regulatory protein-deficient mice","volume":"275","author":"Grimsby","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116499_b0260","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00125-003-1244-z","article-title":"Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance","volume":"46","author":"Ferre","year":"2003","journal-title":"Diabetologia."},{"key":"10.1016\/j.bcp.2024.116499_b0265","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2337\/diabetes.50.3.622","article-title":"Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes","volume":"50","author":"Shiota","year":"2001","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2024.116499_b0270","doi-asserted-by":"crossref","first-page":"32485","DOI":"10.1074\/jbc.R300020200","article-title":"Gene-altered mice and metabolic flux control","volume":"278","author":"Magnuson","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116499_b0275","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2337\/dc16-0153","article-title":"A common gene variant in glucokinase regulatory protein interacts with glucose metabolism on diabetic dyslipidemia: the combined CODAM and Hoorn studies","volume":"39","author":"Simons","year":"2016","journal-title":"Diabetes. Care."},{"key":"10.1016\/j.bcp.2024.116499_b0280","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2024.116499_b0285","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.cell.2022.09.031","article-title":"En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH","volume":"185","author":"Kimura","year":"2022","journal-title":"Cell."},{"key":"10.1016\/j.bcp.2024.116499_b0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db22-0708","article-title":"Dorzagliatin, a Dual-acting glucokinase activator, increases insulin secretion and glucose sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset Type 2 diabetes","volume":"72","author":"Chow","year":"2023","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2024.116499_b0295","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2337\/db21-0992","article-title":"Genetic reduction of glucose metabolism preserves functional \u03b2-cell mass in KATP-induced neonatal diabetes","volume":"71","author":"Yan","year":"2022","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2024.116499_b0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tem.2022.12.007","article-title":"Glucokinase activity in diabetes: too much of a good thing?","volume":"34","author":"Ashcroft","year":"2023","journal-title":"Trends. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0305","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/dom.14459","article-title":"Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?","volume":"23","author":"Nakamura","year":"2021","journal-title":"Diabetes. Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116499_b0310","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2337\/db22-0731","article-title":"Glucokinase inhibition: a novel treatment for diabetes?","volume":"72","author":"Remedi","year":"2023","journal-title":"Diabetes."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T17:16:37Z","timestamp":1741713397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224004829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":62,"alternative-id":["S0006295224004829"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116499","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116499"}}